Wednesday, November 18, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

BrainChip Secures Key Licensing Agreement for Akida-2 Technology

Rodolfo Hanigan by Rodolfo Hanigan
March 31, 2026
in AI & Quantum Computing, Semiconductors, Tech & Software, Trading & Momentum
0
BrainChip Stock
0
SHARES
84
VIEWS
Share on FacebookShare on Twitter

The neuromorphic computing specialist BrainChip has announced a significant commercial milestone, signaling a potential turnaround after a prolonged period of limited news. The company entered into a global licensing agreement with EDGEAI over the weekend, granting access to its next-generation Akida-2 technology. This deal reinforces a fundamental recovery that was initially hinted at in the firm’s latest annual revenue figures.

Under the terms of the non-exclusive partnership, EDGEAI receives comprehensive access to the intellectual property underpinning BrainChip’s Akida architecture. The agreement also includes necessary development tools and software components. Financial returns for BrainChip will come through milestone-based payments linked to technical delivery targets. Once EDGEAI begins commercial shipment of its own products, quarterly royalty payments will commence. While management has not yet quantified the precise financial scope, it anticipates substantial long-term revenue streams from resulting product sales.

Should investors sell immediately? Or is it worth buying BrainChip?

Financial Performance Shows Marked Improvement

This new contract aligns with a broader positive shift in the company’s financial trajectory. The annual report for 2025, published in late February, revealed a dramatic 374 percent surge in revenue to $1.89 million. Concurrently, BrainChip managed to narrow its net loss from $24.43 million to $20.47 million. The company also strengthened its balance sheet, with cash reserves growing to $31.71 million. Investor sentiment has responded with cautious optimism. The equity, currently trading at €0.09, is attempting to stabilize following an approximate 28 percent decline over the preceding twelve-month period.

Operational Milestones on the Horizon

Beyond commercial deals, operational execution is now coming into focus. The company reports that its AKD1500 chip has entered the volume production phase, with final silicon expected in the third quarter of 2026. In parallel, development has commenced on the custom AKD2500 project. First prototypes for this chip are also slated for availability in Q3 2026. These technological advancements form the foundation for BrainChip to more broadly address rising demand for ultra-low-power AI applications within the edge computing sector.

Ad

BrainChip Stock: Buy or Sell?! New BrainChip Analysis from November 17 delivers the answer:

The latest BrainChip figures speak for themselves: Urgent action needed for BrainChip investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 17.

BrainChip: Buy or sell? Read more here...

Tags: BrainChip
Rodolfo Hanigan

Rodolfo Hanigan

Related Posts

Micron Technology Stock
AI & Quantum Computing

Micron’s Rally Faces Its Moment of Reckoning: A Downgrade, a Labor Standoff, and a Date With the Numbers

September 9, 2026
SAP Stock
Analysis

SAP’s Buyback Machine Grinds On, But the Analyst Chorus Is Turning Sour

September 7, 2026
Xiaomi Stock
Asian Markets

Xiaomi’s September Tightrope: A Foldable Counterpunch Against Apple While EV Targets Slip

September 7, 2026
Next Post
Nexus Uranium Stock

Nexus Uranium Shifts Focus to Project Exploration Following Strategic Acquisitions

Orsted Stock

Bank of America Upgrade Ignites Surge in Ørsted Shares

Roche Stock

Roche's Diagnostic Division Gains Momentum with Dual Regulatory Wins

Recommended

Mirum Pharmaceuticals Stock

Mirum Pharmaceuticals: A Pivotal Year of Clinical Catalysts and Financial Milestones

8 months ago
Marvell Technology Stock

Marvell Technology’s AI Business Fuels Record Quarter Amid Mixed Segment Performance

1 year ago
Ondas Holdings Stock

Ondas Holdings: Can New Contracts Reignite Its Stalled Momentum?

12 months ago
Block Stock

A Tale of Two Titans: Block and PayPal’s Divergent Fintech Paths

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

The AI Rebound Gets an Audit: Who Earns, Who Borrows

A Hot CPI Reading Stalls the Rebound and Puts a December Hike in Play

Cash Over Stories: Take-Two, Cisco and Nvidia Face Their Tests

Four Down Weeks for the Nasdaq, and Consumer Stocks Quietly Cash In

Trending

Home Depot Stock
Newsletter

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

by Stephanie Dugan
November 17, 2026
0

Dear readers, Home Depot did what it was supposed to do on Tuesday morning and got little...

Bitcoin Stock

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

November 16, 2026
Cisco Stock

At 5.15%, the 10-Year Treasury Picks the Winners

November 14, 2026
Bitcoin Stock

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

November 13, 2026
Cisco Stock

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

November 12, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers
  • Rotation, Not Panic: Retailers Test Where Tech’s Money Went
  • At 5.15%, the 10-Year Treasury Picks the Winners

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com